DDInter1042 DDInter1083
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.
Lofexidine {u} (Compound) resembles {v} (Compound) Apraclonidine
Lofexidine {u} (Compound) binds {v} (Gene) ADRA2A
Lofexidine {u} (Compound) upregulates {v} (Gene) HMGA2
Lofexidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Lofexidine (Compound) resembles Apraclonidine (Compound)
Lofexidine (Compound) binds ADRA2A (Gene)
Lofexidine (Compound) upregulates HMGA2 (Gene)
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Lofexidine may lead to a major life threatening interaction when taken with Ribociclib
Lofexidine may lead to a major life threatening interaction when taken with Toremifene